{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:15:39Z","timestamp":1793938539802,"version":"4.8.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjpad.2025.100195","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:57:51Z","timestamp":1746111471000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Chih-Wei","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4136-1251","authenticated-orcid":false,"given":"Tien-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Tao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7693-1408","authenticated-orcid":false,"given":"Chia-Kuang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-474X","authenticated-orcid":false,"given":"Yu-Kang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5586","authenticated-orcid":false,"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10284","key":"10.1016\/j.tjpad.2025.100195_bib0001","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100195_bib0002","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer's therapeutics (Review)","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3233\/ADR-210061","article-title":"Neuroprotective Effects of Cholinesterase Inhibitors: current Scenario in Therapies for Alzheimer's Disease and Future Perspectives","volume":"6","author":"Moreira","year":"2022","journal-title":"J Alzheimers Dis Rep"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100195_bib0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00019442-200303000-00004","article-title":"Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations","volume":"11","author":"Cummings","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100195_bib0005","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2008.12.003","article-title":"Defining and labeling disease-modifying treatments for Alzheimer's disease","volume":"5","author":"Cummings","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0006","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100195_bib0007","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3233\/JAD-190546","article-title":"Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:a Systematic Review and Meta-Analysis","volume":"71","author":"Matsunaga","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100195_bib0008","article-title":"Donanemab: FDA experts recommend approval of Alzheimer\u2019s drug","author":"Dyer","year":"2024","journal-title":"British Medical Journal Publishing Group;"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update","volume":"30","author":"Huang","year":"2023","journal-title":"J Biomed Sci"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100195_bib0010","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.tjpad.2025.100195_bib0011","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"7618","key":"10.1016\/j.tjpad.2025.100195_bib0012","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100195_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100195_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101996","article-title":"Passive Alzheimer's immunotherapy: a promising or uncertain option?","volume":"90","author":"Hoilund-Carlsen","year":"2023","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.tjpad.2025.100195_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101959","article-title":"Effects of three kinds of anti-amyloid-beta drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: a systematic review and meta-analysis of phase II\/III clinical trials in Alzheimer's disease","volume":"88","author":"Lyu","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-024-01067-2","article-title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: a Systematic Review and Network Meta-Analysis","volume":"38","author":"Qiao","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.tjpad.2025.100195_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102203","article-title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis","volume":"94","author":"Terao","year":"2024","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100195_bib0019","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3233\/JAD-240161","article-title":"Pharmacologic and Nutritional Interventions for Early Alzheimer's Disease: a Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"99","author":"Zeng","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.tjpad.2025.100195_bib0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjpad.2025.100195_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101959","article-title":"Effects of three kinds of anti-amyloid-\u03b2 drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: a systematic review and meta-analysis of phase II\/III clinical trials in Alzheimer's disease","volume":"88","author":"Lyu","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100195_bib0022","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer's disease facts and figures","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jrsm.46","article-title":"Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability","volume":"2","author":"Thorlund","year":"2011","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.tjpad.2025.100195_bib0024","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100195_bib0025","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1002\/alz.13770","article-title":"Minimal clinically important difference in Alzheimer's disease: rapid review","volume":"20","author":"Muir","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0026","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo","year":"2020","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"10.1016\/j.tjpad.2025.100195_bib0027","doi-asserted-by":"crossref","unstructured":"Phillippo D.M. multinma: bayesian network meta-analysis of individual and aggregate data. 2020.","DOI":"10.32614\/CRAN.package.multinma"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0028","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12874-020-01128-2","article-title":"Spie charts for quantifying treatment effectiveness and safety in multiple outcome network meta-analysis: a proof-of-concept study","volume":"20","author":"Daly","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100195_bib0029","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1002\/alz.13755","article-title":"Results from the long-term extension of PRIME: a randomized Phase 1b trial of aducanumab","volume":"20","author":"Chen","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100195_bib0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0031","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100195_bib0032","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jagp.2018.05.008","article-title":"Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: a Randomized Controlled Trial","volume":"26","author":"Devanand","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"issue":"18","key":"10.1016\/j.tjpad.2025.100195_bib0033","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/01.wnl.0000344650.95823.03","article-title":"Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial","volume":"72","author":"Doody","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100195_bib0034","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","article-title":"Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study","volume":"6","author":"Feldman","year":"2007","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100195_bib0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12603-012-0062-8","article-title":"A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI","volume":"16","author":"Peters","year":"2012","journal-title":"J Nutr Health Aging"},{"issue":"23","key":"10.1016\/j.tjpad.2025.100195_bib0036","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100195_bib0037","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/01.WNL.0000134664.80320.92","article-title":"Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial","volume":"63","author":"Salloway","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100195_bib0038","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol"},{"issue":"22","key":"10.1016\/j.tjpad.2025.100195_bib0039","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0040","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ana.21953","article-title":"Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease","volume":"67","author":"Vemuri","year":"2010","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0041","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neulet.2010.02.016","article-title":"Amyloid load in nondemented brains correlates with APOE e4","volume":"473","author":"Caselli","year":"2010","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-Related Imaging Abnormalities and beta-Amyloid-Targeting Antibodies: a Systematic Review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100195_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073892","article-title":"Alzheimer's Amyloid Hypothesis and Antibody Therapy: melting Glaciers?","volume":"25","author":"Hoilund-Carlsen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100195_bib0044","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100195_bib0045","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100195_bib0046","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100195_bib0047","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.17219\/acem\/198674","article-title":"Anti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics","volume":"33","author":"Daly","year":"2024","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100195_bib0048","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1370\/afm.3050","article-title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: a Systematic Review and Meta-Analysis","volume":"22","author":"Ebell","year":"2024","journal-title":"Ann Fam Med"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100195_bib0049","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0319-23.2024","article-title":"Lecanemab and Donanemab as Therapies for Alzheimer's Disease: an Illustrated Perspective on the Data","volume":"11","author":"Espay","year":"2024","journal-title":"eNeuro"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100195_bib0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-230099","article-title":"The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100195_bib0051","first-page":"27","article-title":"Second death linked to potential antibody treatment for Alzheimer\u2019s disease","author":"Piller","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.tjpad.2025.100195_bib0052","article-title":"Scientists tie third clinical trial death to experimental Alzheimer\u2019s drug","volume":"21","author":"Piller","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.tjpad.2025.100195_bib0053","article-title":"Conflicts of interest found in FDA committee that approved new Alzheimer's drug","volume":"386","author":"Lenzer","year":"2024","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.tjpad.2025.100195_bib0054","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: a Systematic Review and Meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100195_bib0055","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15007","article-title":"Brain volume loss due to donanemab","volume":"28","author":"Ayton","year":"2021","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100195_bib0056","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3233\/JAD-180105","article-title":"Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimer's Disease Patients","volume":"64","author":"Madsen","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100195_bib0057","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1073\/pnas.0330745100","article-title":"Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model","volume":"100","author":"Reilly","year":"2003","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:37:57Z","timestamp":1762673877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2274580725001402"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100195","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}